Reports revenue $9.76M vs. $11.96M last year. Lisa Conte, Jaguar’s president and CEO, said, “Our paramount near-term clinical activity is our Phase 3 pivotal OnTarget trial of Mytesi for the follow-on indication of the preventative treatment of cancer therapy-related diarrhea, an indication we also refer to as chemotherapy-induced overactive bowel – which includes symptoms such as unpredictable and/or chronic debilitating diarrhea and GI urgency. Top line results from this pivotal study are forthcoming.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar Health signs term sheet for license, commercialization agreement
- Biotech Alert: Searches spiking for these stocks today
- Jaguar Health receives hearing on Nasdaq listing compliance
- Jaguar Health Risks Nasdaq Delisting Over Low Stock Price
- Jaguar announces FDA agreement with clinical trial protocol for Canalevia-CA1
